{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:50Z","timestamp":1793183210354,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jiph.2025.102768","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:09:41Z","timestamp":1744135781000},"page":"102768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"18","author":[{"given":"Ming-ming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-ding","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-qiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-qiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-kui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En-wu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2025.102768_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1756284821989177","article-title":"The status and progress of first-line treatment against Helicobacter pylori infection: a review","volume":"14","author":"Liu","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"issue":"2","key":"10.1016\/j.jiph.2025.102768_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00001-18","article-title":"Helicobacter pylori biofilm formation and its potential role in pathogenesis","volume":"82","author":"Hathroubi","year":"2018","journal-title":"Microbiol Mol Biol Rev"},{"issue":"5","key":"10.1016\/j.jiph.2025.102768_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/17474124.2021.1984878","article-title":"An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders","volume":"16","author":"Savarino","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jiph.2025.102768_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/jgh3.70143","article-title":"Efficacy and safety of 10-day versus 14-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"9","author":"Gohar","year":"2025","journal-title":"JGH Open: Open Access J Gastroenterol Hepatol"},{"key":"10.1016\/j.jiph.2025.102768_bib5","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clin Res Ed)"},{"issue":"1","key":"10.1016\/j.jiph.2025.102768_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12874-021-01260-7","article-title":"Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review","volume":"21","author":"Bai","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"10.1016\/j.jiph.2025.102768_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13133","article-title":"Vonoprazan dual or triple therapy versus bismuth-quadruple therapy as first-line therapy for Helicobacter pylori infection: a three-arm, randomized clinical trial","volume":"29","author":"Cheung","year":"2024","journal-title":"Helicobacter"},{"issue":"12","key":"10.1016\/j.jiph.2025.102768_bib8","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00535-023-02042-2","article-title":"Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multicenter, randomized controlled study","volume":"58","author":"Han","year":"2023","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jiph.2025.102768_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12970","article-title":"Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China","volume":"28","author":"Hu","year":"2023","journal-title":"Helicobacter"},{"issue":"27","key":"10.1016\/j.jiph.2025.102768_bib10","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3748\/wjg.v30.i27.3304","article-title":"Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: a prospective, multicenter, randomized, two-stage study","volume":"30","author":"Huang","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.jiph.2025.102768_bib11","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s10238-023-01074-5","article-title":"Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study","volume":"23","author":"Peng","year":"2023","journal-title":"Clin Exp Med"},{"issue":"4","key":"10.1016\/j.jiph.2025.102768_bib12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy","volume":"118","author":"Qian","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jiph.2025.102768_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13003","article-title":"Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: a propensity score matching analysis","volume":"28","author":"Su","year":"2023","journal-title":"Helicobacter"},{"key":"10.1016\/j.jiph.2025.102768_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231190976","article-title":"Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial","volume":"16","author":"Wang","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"issue":"12","key":"10.1016\/j.jiph.2025.102768_bib15","first-page":"1854","article-title":"Analysis of the application value of vonolaxan combined with high-dose amoxicillin new dual seven day regimen in the treatment of helicobacter pylori infection","volume":"36","author":"Wang","year":"2024","journal-title":"Med J West China"},{"issue":"01","key":"10.1016\/j.jiph.2025.102768_bib16","first-page":"49","article-title":"Observation of therapeutic effect of high-dose dual therapy on Helicobacter pylori","volume":"34","author":"Xiao","year":"2025","journal-title":"Chin J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jiph.2025.102768_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cpdd.1357","article-title":"Clinical study on the eradication of Helicobacter pylori by vonoprazan combined with amoxicillin for 10-day dual therapy","volume":"13","author":"Yan","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.jiph.2025.102768_bib18","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002592","article-title":"Ten-day vonoprazan-amoxicillin dual therapy vs standard 14-day bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial","volume":"119","author":"Yan","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jiph.2025.102768_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241309870","article-title":"Ten-day vonoprazan- amoxicillin dual therapy versus 14-day esomeprazole-amoxicillin dual therapy for first-line Helicobacter pylori eradication: a prospective multicenter randomized controlled trial","volume":"17","author":"Zhou","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jiph.2025.102768_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/00365528909091311","article-title":"Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study","volume":"167","author":"Unge","year":"1989","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"3","key":"10.1016\/j.jiph.2025.102768_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2036.1997.00169.x","article-title":"Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients","volume":"11","author":"Labenz","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jiph.2025.102768_bib22","first-page":"501","article-title":"Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. a multicentre randomized long-term detailed study","volume":"29","author":"Maconi","year":"1997","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jiph.2025.102768_bib23","first-page":"482","article-title":"A randomised trial of amoxycillin versus clarithromycin in combination with omeprazole for eradication of Helicobacter pylori infection in Singapore","volume":"41","author":"Fock","year":"2000","journal-title":"Singap Med J"},{"issue":"2","key":"10.1016\/j.jiph.2025.102768_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori Infection: a network meta-analysis","volume":"161","author":"Rokkas","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jiph.2025.102768_bib25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jiph.2025.102768_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics9060293","article-title":"The puzzle of coccoid forms of Helicobacter pylori: beyond basic science","volume":"9","author":"Ierardi","year":"2020","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.jiph.2025.102768_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00424-008-0495-4","article-title":"The gastric HK-ATPase: structure, function, and inhibition","volume":"457","author":"Shin","year":"2009","journal-title":"Pflug Arch Eur J Physiol"},{"issue":"4","key":"10.1016\/j.jiph.2025.102768_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine","volume":"14","author":"El Rouby","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.jiph.2025.102768_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2036.1997.140316000.x","article-title":"An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively","volume":"11","author":"Miehlke","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jiph.2025.102768_bib30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jiph.2025.102768_bib31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3748\/wjg.v30.i9.1213","article-title":"Treatment of Helicobacter pylori with potassium competitive acid blockers: a systematic review and meta-analysis","volume":"30","author":"Kanu","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jiph.2025.102768_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jiph.2025.102768_bib33","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jiph.2025.102768_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13019","article-title":"Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan","volume":"28","author":"Ratana-Amornpin","year":"2023","journal-title":"Helicobacter"},{"issue":"4Part-II","key":"10.1016\/j.jiph.2025.102768_bib35","first-page":"965","article-title":"Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter pylori eradication: a randomized control trial","volume":"38","author":"Zuberi","year":"2022","journal-title":"Pak J Med Sci"},{"issue":"10","key":"10.1016\/j.jiph.2025.102768_bib36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","article-title":"Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-na\u00efve cohort of junior high school students in Japan","volume":"55","author":"Gotoda","year":"2020","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jiph.2025.102768_bib37","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jiph.2025.102768_bib38","first-page":"55","article-title":"Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: a single-arm, interventional study","volume":"7","author":"Sue","year":"2023","journal-title":"JGH Open Open Access J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jiph.2025.102768_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13039","article-title":"Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: a systematic review and meta-analysis","volume":"29","author":"Du","year":"2024","journal-title":"Helicobacter"},{"issue":"1","key":"10.1016\/j.jiph.2025.102768_bib40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s40001-023-01249-6","article-title":"The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis","volume":"28","author":"Feng","year":"2023","journal-title":"Eur J Med Res"},{"issue":"9","key":"10.1016\/j.jiph.2025.102768_bib41","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/jgh.15917","article-title":"Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"37","author":"Ouyang","year":"2022","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125001170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125001170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:06:42Z","timestamp":1780873602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034125001170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1876034125001170"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102768","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102768"}}